These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 8348684)

  • 1. Extracorporeal circulation: in vivo and in vitro analysis of complement activation by heparin-bonded surfaces.
    Kirschfink M; Kovacs B; Mottaghy K
    Circ Shock; 1993 Jul; 40(3):221-6. PubMed ID: 8348684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin-coated circuits reduce complement activation and inflammatory response to cardiopulmonary bypass.
    Tamim M; Demircin M; Guvener M; Peker O; Yilmaz M
    Panminerva Med; 1999 Sep; 41(3):193-8. PubMed ID: 10568115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement activation during extracorporeal circulation. In vitro comparison of Duraflo II heparin-coated and uncoated oxygenator circuits.
    Svennevig JL; Geiran OR; Karlsen H; Pedersen T; Mollnes TE; Kongsgard U; Frøysaker T
    J Thorac Cardiovasc Surg; 1993 Sep; 106(3):466-72. PubMed ID: 8361189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biocompatibility of extracorporeal circulation. In vitro comparison of heparin-coated and uncoated oxygenator circuits.
    Videm V; Mollnes TE; Garred P; Svennevig JL
    J Thorac Cardiovasc Surg; 1991 Apr; 101(4):654-60. PubMed ID: 2008104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of complement activation during extracorporeal blood-biomaterial interaction: effects of heparin coated and uncoated surfaces.
    Kopp R; Mottaghy K; Kirschfink M
    ASAIO J; 2002; 48(6):598-605. PubMed ID: 12455769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific complement inhibition with heparin-coated extracorporeal circuits.
    te Velthuis H; Jansen PG; Hack CE; Eijsman L; Wildevuur CR
    Ann Thorac Surg; 1996 Apr; 61(4):1153-7. PubMed ID: 8607674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of three oxygenator-coated and one total-circuit-coated extracorporeal devices.
    Baksaas ST; Videm V; Pedersen T; Karlsen H; Mollnes TE; Brosstad F; Svennevig JL
    Perfusion; 1999 Mar; 14(2):119-27. PubMed ID: 10338323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin-coated versus non-coated surfaces for extracorporeal circulation.
    Mottaghy K; Oedekoven B; Pöppel K; Kovacs B; Kirschfink M; Bruchmüller K; Kashefi A; Geisen C
    Int J Artif Organs; 1991 Nov; 14(11):721-8. PubMed ID: 1757160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation.
    Lappegård KT; Fung M; Bergseth G; Riesenfeld J; Lambris JD; Videm V; Mollnes TE
    Ann Thorac Surg; 2004 Mar; 77(3):932-41. PubMed ID: 14992902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative pathway of complement is activated during in vitro ventricular assist.
    Chen JC; Huynh TN; Serna DL; Sun CP; Ha H; Steward E; Webster S; Brenner M
    J Investig Med; 1999 Nov; 47(9):502-6. PubMed ID: 10572381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hirudin versus heparin for use in whole blood in vitro biocompatibility models.
    Bexborn F; Engberg AE; Sandholm K; Mollnes TE; Hong J; Nilsson Ekdahl K
    J Biomed Mater Res A; 2009 Jun; 89(4):951-9. PubMed ID: 18470919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of factor Xa inhibitors on thrombin formation and complement and neutrophil activation during in vitro extracorporeal circulation.
    Gikakis N; Khan MM; Hiramatsu Y; Gorman JH; Hack CE; Sun L; Rao AK; Niewiarowski S; Colman RW; Edmunds LH
    Circulation; 1996 Nov; 94(9 Suppl):II341-6. PubMed ID: 8901772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A protamine filter for extracorporeal heparin removal. Development, testing, blood compatibility evaluation, and future direction.
    Byun Y; Yun JH; Han IS; Fu Y; Shanberge JN; Yang VC
    ASAIO J; 1995; 41(3):M301-5. PubMed ID: 8573812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Veno-venous bypass in liver transplantation: heparin-coated perfusion circuits reduce the activation of humoral defense systems in an in vitro model.
    Scholz T; Solberg R; Okkenhaug C; Videm V; Gallimore MJ; Mathisen O; Pedersen T; Mollnes TE; Bergan A; Søreide O; Klintmalm GB; Aasen AO
    Perfusion; 2001 Jul; 16(4):285-92. PubMed ID: 11486847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the function of activated properdin by squid chondroitin sulfate E glycosaminoglycan and murine bone marrow-derived mast cell chondroitin sulfate E proteoglycan.
    Wilson JG; Fearon DT; Stevens RL; Seno N; Austen KF
    J Immunol; 1984 Jun; 132(6):3058-63. PubMed ID: 6427331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomaterial-dependent blood activation during simulated extracorporeal circulation: a study of heparin-coated and uncoated circuits.
    Borowiec JW; Venge P; Henze A; Nilsson B; Stiernström H
    Thorac Cardiovasc Surg; 1997 Dec; 45(6):295-301. PubMed ID: 9477462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of surface bound complement at increasing serum anticoagulant concentrations.
    Arvidsson S; Askendal A; Lindahl TL; Tengvall P
    Colloids Surf B Biointerfaces; 2008 Apr; 62(2):214-9. PubMed ID: 18006286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Centrifugal pump and heparin coating improves cardiopulmonary bypass biocompatibility.
    Moen O; Fosse E; Dregelid E; Brockmeier V; Andersson C; Høgåsen K; Venge P; Mollnes TE; Kierulf P
    Ann Thorac Surg; 1996 Oct; 62(4):1134-40. PubMed ID: 8823102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylcholine or heparin coating for pediatric extracorporeal circulation causes similar biologic effects in neonates and infants.
    Böning A; Scheewe J; Ivers T; Friedrich C; Stieh J; Freitag S; Cremer JT
    J Thorac Cardiovasc Surg; 2004 May; 127(5):1458-65. PubMed ID: 15116008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement component C2, inhibiting a latent serine protease in the classical pathway of complement activation.
    Halili MA; Ruiz-Gómez G; Le GT; Abbenante G; Fairlie DP
    Biochemistry; 2009 Sep; 48(35):8466-72. PubMed ID: 19642650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.